文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗中重度银屑病患者100周的安全性:VOYAGE 1和VOYAGE 2随机研究的汇总分析

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
PubMed 文献 · Br J Dermatol · 2019-01-01

汇总VOYAGE 1和VOYAGE 2随机对照研究100周随访的安全性数据,比较古塞奇尤单抗与阿达木单抗及古塞奇尤单抗长期治疗的不良事件发生率。结果显示古塞奇尤单抗安全性特征良好,阿达木单抗交叉至古塞奇尤单抗后未见新安全信号。

要点

  • 古塞奇尤单抗治疗100周安全性特征良好。
  • 第52周时古塞奇尤单抗组不良事件发生率低于阿达木单抗组。
  • 阿达木单抗交叉至古塞奇尤单抗后未见新安全信号。

核心结论

  • 古塞奇尤单抗在中重度银屑病患者中治疗100周的安全性特征保持良好。

研究设计与样本

  • 汇总VOYAGE 1(NCT02207231)和VOYAGE 2(NCT02207244)两项随机试验的100周随访安全性数据。
  • 患者随机接受古塞奇尤单抗100 mg(第0、4周及之后每8周)、安慰剂后古塞奇尤单抗100 mg或阿达木单抗80 mg(第0周)、40 mg(第1周)及之后每2周40 mg。
  • 阿达木单抗组患者在VOYAGE 1第52周、VOYAGE 2第28周或之后根据临床应答交叉至古塞奇尤单抗。
  • 开放标签扩展阶段所有患者均接受古塞奇尤单抗,VOYAGE 1自第52周开始,VOYAGE 2自第76周开始。

主要发现

  • 截至第52周,古塞奇尤单抗组与阿达木单抗组不良事件发生率分别为每100患者年262.45和328.28。
  • 截至第52周,古塞奇尤单抗组与阿达木单抗组严重不良事件发生率分别为每100患者年6.20和7.77。
  • 截至第52周,古塞奇尤单抗组与阿达木单抗组严重感染发生率分别为每100患者年1.22和1.79。
  • 截至第52周,古塞奇尤单抗组与阿达木单抗组非黑色素瘤皮肤癌以外恶性肿瘤发生率分别为每100患者年0.28和0.40,非黑色素瘤皮肤癌发生率分别为每100患者年0.56和0.40,主要不良心血管事件发生率分别为每100患者年0.47和0.40。
  • 古塞奇尤单抗组截至第52周与第100周的不良事件发生率分别为每100患者年262.45和210.41,严重不良事件分别为每100患者年6.20和6.29,严重感染分别为每100患者年1.22和1.06,恶性肿瘤分别为每100患者年0.28和0.38,非黑色素瘤皮肤癌分别为每100患者年0.56和0.39,主要不良心血管事件分别为每100患者年0.47和0.38。

关键数值与推荐

  • 古塞奇尤单抗给药方案:100 mg于第0、4周及之后每8周一次。
  • 阿达木单抗给药方案:第0周80 mg,第1周40 mg,之后每2周40 mg。
  • 阿达木单抗交叉至古塞奇尤单抗时间:VOYAGE 1第52周;VOYAGE 2第28周或之后根据临床应答。
  • 开放标签扩展开始时间:VOYAGE 1第52周;VOYAGE 2第76周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term evaluation is required to confirm the safety profile of newer biologic agents. OBJECTIVES: To report on pooled safety data from the ongoing VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials through 100 weeks of follow-up. METHODS: Patients were randomized to either guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter; placebo at weeks 0, 4, 12 followed by guselkumab 100 mg at weeks 16 and 20 and every 8 weeks thereafter; or adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter. Patients who received adalimumab crossed over to guselkumab at week 52 (VOYAGE 1) and at/after week 28 based on clinical response (VOYAGE 2). Open-label extensions, in which all patients received guselkumab, started at week 52 (VOYAGE 1) and week 76 (VOYAGE 2). Rates of adverse events (AEs) per 100 patient-years (PYs) are presented through 100 weeks of follow-up. RESULTS: Through week 52, observed rates for guselkumab- and adalimumab-treated patients, respectively, were 262·45 per 100 PYs and 328·28 per 100 PYs for AEs, 6·20 per 100 PYs and 7·77 per 100 PYs for serious AEs (SAEs), 1·22 per 100 PYs and 1·79 per 100 PYs for serious infections (SIs), 0·28 per 100 PYs and 0·40 per 100 PYs for malignancies other than nonmelanoma skin cancers (NMSCs), 0·56 per 100 PYs and 0·40 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·40 per 100 PYs for major adverse cardiovascular events (MACEs). Rates among patients treated with guselkumab through week 52 and week 100, respectively, were 262·45 per 100 PYs and 210·41 per 100 PYs for AEs, 6·20 and 6·29 per 100 PYs, for SAEs, 1·22 per 100 PYs and 1·06 per 100 PYs for SIs, 0·28 per 100 PYs and 0·38 per 100 PYs for malignancies, 0·56 per 100 PYs and 0·39 per 100 PYs for NMSCs, and 0·47 per 100 PYs and 0·38 per 100 PYs for MACEs. Among patients treated with adalimumab, rates of AEs, SAEs, SIs, malignancies, NMSCs, and MACEs showed some variability before and after crossover to guselkumab, although no new safety signals were noted after crossover. CONCLUSIONS: The safety profile for guselkumab remains favourable through 100 weeks of treatment in patients with moderate-to-severe psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019. PMID: 30485400. doi:10.1111/bjd.17454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。